CO7160102A2 - Fármaco para prevenir y/o tratar la enfermedad renal poliquística - Google Patents

Fármaco para prevenir y/o tratar la enfermedad renal poliquística

Info

Publication number
CO7160102A2
CO7160102A2 CO14284574A CO14284574A CO7160102A2 CO 7160102 A2 CO7160102 A2 CO 7160102A2 CO 14284574 A CO14284574 A CO 14284574A CO 14284574 A CO14284574 A CO 14284574A CO 7160102 A2 CO7160102 A2 CO 7160102A2
Authority
CO
Colombia
Prior art keywords
kidney disease
drug
polycystic kidney
prevent
treat polycystic
Prior art date
Application number
CO14284574A
Other languages
English (en)
Inventor
Hiroyuki Fujiki
Miki Aihara
Shizuo Kinoshita
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of CO7160102A2 publication Critical patent/CO7160102A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un objeto de la presente invención es proporcionar unacombinación de fármacos que tiene notablemente efectosterapéuticos y/o preventivos excelentes en la enfermedad renalpoliquística. La presente invención brinda un fármaco paraprevenir y/o tratar la enfermedad renal poliquística quecomprende una combinación de tolvaptán o uno de sus profármacoscon un derivado de somatostatina, y un método para tratar laenfermedad renal poliquística utilizando dicho fármaco
CO14284574A 2012-05-31 2014-12-29 Fármaco para prevenir y/o tratar la enfermedad renal poliquística CO7160102A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653524P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
CO7160102A2 true CO7160102A2 (es) 2015-01-15

Family

ID=48670042

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14284574A CO7160102A2 (es) 2012-05-31 2014-12-29 Fármaco para prevenir y/o tratar la enfermedad renal poliquística

Country Status (31)

Country Link
US (7) US9636382B2 (es)
EP (1) EP2854815B1 (es)
JP (4) JP6116591B2 (es)
KR (2) KR102127180B1 (es)
CN (2) CN104334176B (es)
AR (1) AR091205A1 (es)
AU (3) AU2013268343B2 (es)
BR (1) BR112014029573A2 (es)
CA (1) CA2873365A1 (es)
CO (1) CO7160102A2 (es)
CY (1) CY1120490T1 (es)
DK (1) DK2854815T3 (es)
EA (1) EA036062B1 (es)
ES (1) ES2654768T3 (es)
HK (1) HK1206992A1 (es)
HR (1) HRP20180040T1 (es)
HU (1) HUE035158T2 (es)
IL (2) IL235623A0 (es)
LT (1) LT2854815T (es)
MX (1) MX366121B (es)
MY (1) MY174625A (es)
NO (1) NO2888775T3 (es)
NZ (1) NZ630118A (es)
PH (2) PH12014502558A1 (es)
PL (1) PL2854815T3 (es)
PT (1) PT2854815T (es)
SG (2) SG11201407368VA (es)
SI (1) SI2854815T1 (es)
TW (2) TWI633887B (es)
WO (1) WO2013180310A1 (es)
ZA (1) ZA201408411B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343982B1 (en) 2008-09-17 2017-03-22 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
WO2014104412A1 (en) 2012-12-28 2014-07-03 Otsuka Pharmaceutical Co., Ltd. Injectable depot formulation comprising optically active tolvaptan and process of producing the same
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
CA2975599A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
EP3405211A4 (en) * 2016-01-21 2019-10-09 Chiasma Inc. ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASES
WO2019118272A1 (en) * 2017-12-11 2019-06-20 Mayo Foundation For Medical Education And Research Using probenecid to treat polycystic kidney disease
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
EP4015860A4 (en) 2019-08-14 2022-09-28 Autodyn Sys Inc. LOCKING THE CLUTCH SYSTEM WITH THE ACCELERATOR PEDAL AND THE BRAKE PEDAL
US11781606B2 (en) 2019-10-16 2023-10-10 Autodyn Sys Inc. Rotary shaft assembly
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US20230158041A1 (en) * 2021-11-22 2023-05-25 Otsuka Pharmaceutical Co.,Ltd. Methods and compositions for treating autosomal dominant polycystic kidney disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450097B1 (en) 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
JP4154765B2 (ja) 1998-09-28 2008-09-24 ダイキン工業株式会社 天井取付型の空気吹出器
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
ES2533007T3 (es) 2005-12-27 2015-04-06 Otsuka Pharmaceutical Co., Ltd. Compuesto de benzoacepina soluble en agua y su composición farmacéutica
GB0602639D0 (en) 2006-02-09 2006-03-22 Novartis Ag Organic compounds
EP2007370B1 (en) 2006-03-31 2013-12-18 Erasmus University Medical Center Rotterdam Novel composition for tumor growth control
AU2007255416A1 (en) 2006-06-08 2007-12-13 Novartis Ag Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物

Also Published As

Publication number Publication date
CN107625953A (zh) 2018-01-26
IL235623A0 (en) 2015-01-29
SG11201407368VA (en) 2015-01-29
TW201827056A (zh) 2018-08-01
US20160058841A1 (en) 2016-03-03
PT2854815T (pt) 2017-12-20
NO2888775T3 (es) 2018-08-04
US20190117666A1 (en) 2019-04-25
PL2854815T3 (pl) 2018-03-30
US20190374549A1 (en) 2019-12-12
US11013746B2 (en) 2021-05-25
IL253441A0 (en) 2017-09-28
KR102211354B1 (ko) 2021-02-03
KR20200034811A (ko) 2020-03-31
MX366121B (es) 2019-06-27
BR112014029573A2 (pt) 2017-06-27
US9669075B2 (en) 2017-06-06
NZ630118A (en) 2016-07-29
PH12014502558B1 (en) 2015-01-21
SG10201609250QA (en) 2016-12-29
US9636382B2 (en) 2017-05-02
JP6116591B2 (ja) 2017-04-19
EA036062B1 (ru) 2020-09-22
CN104334176A (zh) 2015-02-04
SI2854815T1 (en) 2018-02-28
WO2013180310A1 (en) 2013-12-05
KR102127180B1 (ko) 2020-06-29
PH12014502558A1 (en) 2015-01-21
CA2873365A1 (en) 2013-12-05
HRP20180040T1 (hr) 2018-02-09
AU2019202158B2 (en) 2020-06-25
TWI704919B (zh) 2020-09-21
CN104334176B (zh) 2018-01-02
EA201492279A1 (ru) 2015-05-29
EP2854815B1 (en) 2017-11-22
JP6724085B2 (ja) 2020-07-15
ES2654768T3 (es) 2018-02-15
US20170239265A1 (en) 2017-08-24
HK1206992A1 (en) 2016-01-22
AR091205A1 (es) 2015-01-21
US11957691B2 (en) 2024-04-16
JP2017110029A (ja) 2017-06-22
TWI633887B (zh) 2018-09-01
HUE035158T2 (hu) 2018-05-02
AU2013268343A1 (en) 2014-11-27
JP2015517974A (ja) 2015-06-25
US20220241293A1 (en) 2022-08-04
DK2854815T3 (en) 2018-01-22
JP6938705B2 (ja) 2021-09-22
CY1120490T1 (el) 2019-07-10
MY174625A (en) 2020-05-03
TW201400118A (zh) 2014-01-01
ZA201408411B (en) 2016-09-28
US20150141338A1 (en) 2015-05-21
US11147821B2 (en) 2021-10-19
US20170196877A1 (en) 2017-07-13
LT2854815T (lt) 2018-02-12
AU2013268343B2 (en) 2017-06-01
AU2019202158A1 (en) 2019-04-18
EP2854815A1 (en) 2015-04-08
JP2019001801A (ja) 2019-01-10
KR20150016597A (ko) 2015-02-12
MX2014014476A (es) 2015-02-12
JP2020117535A (ja) 2020-08-06
AU2017202757A1 (en) 2017-05-18
PH12018501227A1 (en) 2020-09-14

Similar Documents

Publication Publication Date Title
CO7160102A2 (es) Fármaco para prevenir y/o tratar la enfermedad renal poliquística
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
CL2013002612A1 (es) Compuestos derivados de c4-monometil triterpenoides; composicion farmaceutica que los comprende; y metodo para tratar o prevenir una enfermedad o un trastorno.
BR112018004620A2 (pt) moduladores da expressão de kras
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
GT201200220A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
CR20120202A (es) Métodos y composiciones para tratar cáncer
BR112015011271A2 (pt) cortina medicinal, sistema para o tratamento de um tecido local com a pressão reduzida, método para fabricar uma cortina medicinal, e método para o tratamento de um tecido local com a pressão reduzida
BR112015007061A2 (pt) composto, composição farmacêutica e método para tratar uma condição ou distúrbio dependente de apkc em um paciente
BR102012031038B1 (pt) Métodos para tratamento de emissões de processamento de carvão e dispositivos e sistemas associados
EP2906365A4 (en) METHOD AND SYSTEMS FOR TREATING BURNTED WASTE
BR112015001596A2 (pt) composição para o tratamento de hiperlipidemia que compreende oxintomodulina.
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.